• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Reed-Lane

    Almac Group

    Cytovance Biologics

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Cytovance Biologics

    Baxter BioPharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Parenteral Drug Trends

    Leading CDMOs discuss trends in the market for injectable drugs.

    Parenteral Drug Trends
    (Photo courtesy of LSNE)
    Tim Wright, Editor, Contract Pharma03.04.20
    Parenteral drugs are types of medications that require non-oral administration, mostly through the direct injection of drugs into the body of the patient either in intravenous, intramuscular, and subcutaneous methods.

    After oral administration, parenteral drug delivery is the most common way of getting drugs to patients. While more complex and costly to make than their oral counter-parts, parenteral drugs tout many advantages, such as greater bioavailability.

    The market for injectables has been growing steadily over the last decade and projected growth is strong and being driven by the increasing number of drugs approved each year and the booming biologics space.

    The emergence of orphan drug development to treat rare diseases is another area sparking growth, according to Marga Viñes, business development manager, contract manufacturing, Grifols International. “Recent successes in the development of orphan drugs coupled with productivity challenges in the classic pharma R&D model for indications with a higher prevalence have resulted in a number of major pharmaceutical companies establishing business units focused on rare diseases,” she said. “Investment by venture capital companies in early-stage biotechs with rare disease programs has also increased.”

    Increasing complexity of formulations and associated clinical trial process complications have limited the entry of new players within the parenteral field, according to Ms. Viñes. With increasing outsourcing activities, contract manufacturing companies are likely to gain advantage compared to in-house manufacturing facilities in the coming years.

    “The parenteral drug market continues to grow, but we’re seeing growth of the outsourced market surpassing the industry growth in general,” said Bert Barbosa, vice president, drug product, Ajinomoto Bio-Pharma Services. “There is an increasing number of emerging biopharmas that are developing products through late stage and thus requiring contract development and manufacturing organization (CDMO) support, as opposed to larger pharmas with internal manufacturing capabilities.”

    Jeff Clement, president of business development, LSNE Contract Manufacturing, said the market continues to move towards fully integrated CDMOs for not only the GMP manufacturing of their product, but for supporting formulation development, analytical development, and quality control services. “Vendor management is a critical concern for many companies seeking to reduce costs and manage their clinical or commercial supply efficiently,” he said.

    Growth drivers
    Personalized medicine looks to be a large part of the future of drug development and an area where CDMOs can invest heavily to support patient needs. “CDMO support will be needed to help development companies navigate the difficult regulatory, time and quality hurdles that currently raise concerns,” said Mr. Barbosa, “but the companies that are early adopters of innovative solutions between customers and regulatory authorities will be poised for taking advantage of this growing sector.

    Also, he said the number of oncology and potent drugs in development has dwarfed other therapeutic areas over the last decade, and that trend is likely to continue. “Within oncology there are HPAPI and ADC drugs that are poised for significant growth.”

    Today’s CDMO needs to stay abreast of trends in new formulations or drug delivery technologies. To that end, strong CDMOs will have technologies to support liposomal formulations, emulsions, suspensions, as well as new drug products being formulated with a variety of cyclodextrins, according to Mr. Clement.

    “Many companies have developed platform technologies, which are used for many products within the company’s pipeline,” he said. “LSNE has kept pace by developing programs which initiates a comprehensive lyophilization development program for the initial platform product and then performing an assessment of other APIs developed on our client’s platform technology. CDMOs working collaboratively with the developer on complex/aseptically processed projects are driving the business towards long term partnerships rather than one-off fills.”

    At the same time, some companies seem to be moving toward more complex administration systems. These novel pre-filled devices are more user-friendly for the patient and can help the company distinguish themselves from their competition, Mr. Clement said. “However, the early clinical stage production costs may be very high so many companies delay the decision to move towards these novel delivery systems until they have completed successful clinical trials with more traditional methods of administration. We anticipate that companies will continue to explore novel prefill devices but there will be challenges with filling them aseptically and lyophilizing them, if required.” 

    In recent years, Ms. Viñes reiterated that drug makers have shifted their focus from the development of blockbuster drugs to the development of therapies to treat rare diseases, also known as orphan drugs. “There have been 7000–8000 rare diseases identified to date—effective medicines have been developed for only a few hundred of these diseases,” she said.

    Concerning biologics, Ms. Viñes said that as a result of positive development and success in treatment of a majority of chronic diseases, “a large number of companies have been investing in research and development for these products.”

    The generics front offers other opportunities for growth. “Over the next 5 years, more than 30 drugs are likely to lose patent and go generic,” said Ms. Viñes. “With so many molecules converting to generics, there will be a lot of potential business for contract manufacturers focused on these types of drugs to capitalize on.”

    Market challenges
    By all accounts the market for the development and manufacture of injectable drugs is poised for tremendous growth. Despite the positive outlook, the CDMOs servicing the space face numerous challenges getting drugs to market.

    An increase in cost bases and the demand for investments to support larger and more diverse service offerings is posing a significant obstacle, according to Mr. Barbosa. “Clinical customers who need flexible support services require cost effective means of working with a CDMO partner to deal with clinical issues that arise,” he said. “CDMOs then must have manufacturing and quality systems that can adapt to the customer’s needs.”

    He continued, “Commercial customers face increasing pressure globally from regulators on costs of drugs and therefore need to partner with CDMOs to find mutually beneficial solutions to controlling costs and sharing savings over the life time of a drug. CDMO’s are in a tough position because they must try to accommodate the wide-ranging needs of clinical clients, but also have efficiencies in commercial manufacturing to cut costs down for partners and patients.”

    As regulatory requirements continue to tighten, Mr. Clement says he expects to see a greater emphasis on isolators and automated equipment which will reduce human intervention. “Our clients are focused on their timelines and speed to market so continuing to provide them with timely service will be paramount,” he said. “There will likely be a focus on innovation and both existing and new CMOs will need to have growth plans and options in place to move quickly with an expanded customer base or new technology. Also, with many more novel, complex projects coming to the market there will be a trend towards partnerships between CMOs and their clients.”

    Based on what he’s seen in the market over the last three years, Mr. Clement says he expects that the CMO industry will continue to grow, especially in the areas of fill/finish and lyophilization, to support parenteral drug product manufacturing. 

    As noted earlier, the manufacture of sterile parenteral products is generally more complex than the production of oral dosage forms. Patients, healthcare providers, suppliers and regulators have an implicit requirement of injectable drugs about their safety and effectiveness, according to Ms. Viñes.

    “A culture of quality and effective quality systems are essential for successful production of complex products such as sterile injectable,” she said. “It is imperative that all parenteral products be manufactured to the highest quality standards, regardless of whether they are branded drugs or generics. This demand includes the manufacture of injectable pharmaceuticals in compliance with uncompromising strict standards.” 
    Related Searches
    • Clinical Trials
    • Filling
    • Drug Delivery
    • clinical trial process

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Pfizer, BioNTech Enter Vax Pact With COVAX
    • CONTINUUS Awarded $69.3M DoD Grant
    • Piramal Inks Clinical Supply Deal With Theratechnologies
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login